Preparing the published article.
Company Profile: Intuitive Surgical, Inc.
A public-source profile of Intuitive Surgical covering da Vinci surgery, Ion bronchoscopy, dated international activity and procurement considerations, with manufacturer information and device-specific FDA documentation.
1. Company focus and buyer relevance
Intuitive Surgical develops robotic technology for minimally invasive care. Headquartered in Sunnyvale, California, its portfolio includes the da Vinci surgical systems and the Ion endoluminal system, alongside education and services. These product families address different clinical workflows, so a hospital assessment should identify the intended department and procedure before comparing equipment. Official company overview.
2. Da Vinci systems and surgeon control
The current da Vinci portfolio includes multiport da Vinci 5, Xi and X systems, plus the single-port SP system. SP combines three multijointed instruments and an articulating endoscope through a single robotic arm. Model selection affects access, instruments and room planning; features should not be transferred between models. Da Vinci portfolio.
The surgeon uses the console to view the operative field and control instruments and the endoscope. Intuitive describes an immersive stereo viewer and communication with the operating-room team. This is physician-operated equipment, and console design alone does not establish a clinical advantage over another approach. Console operation and disclosures.
3. Ion addresses a separate bronchoscopy workflow
Ion is a robotic-assisted bronchoscopy system used to obtain lung tissue for biopsy. Intuitive describes planning software that turns a CT scan into a three-dimensional airway map; the physician selects a route to a target and navigates a catheter through the airways. Biopsy sampling supports diagnostic work. It should not be described as equivalent to da Vinci tissue surgery or as a guarantee of diagnosis or cancer treatment. How Ion works.
4. Training and operating-room preparation
Intuitive offers technology learning pathways for surgeons, residents, fellows and operating-room teams, including bedside assistants and robotic coordinators. Intuitive Learning provides online resources, while SimNow supports simulation practice. The manufacturer explains that equipment training does not replace medical training, experience or hospital credentialing. Learning pathways and training limits.
For procurement, request a written plan covering team roles, training access, supervised introduction, compatible instruments, cleaning and sterilization, and technical support. These are evaluation questions for the institution, rather than a promise that a particular package includes every service. Instrument processing must follow the applicable instructions. Instrument-processing responsibilities.
5. Dated international applications and developments
On 7 August 2023, Intuitive reported initial UK Ion procedures within an NHS clinical study at Royal Brompton Hospital and St Bartholomew's Hospital. This is a dated study example, not evidence that every hospital offers Ion or that a study objective has been achieved. Official UK study announcement.
Intuitive announced da Vinci 5's European CE mark on 2 July 2025. A separate announcement on 8 September 2026 concerned CE-marked Force Feedback instruments and further European system enhancements. The distinction matters: a system launch, an instrument clearance and a local feature rollout are separate events. 2025 system announcement; 2026 instrument announcement.
6. Regulatory evidence must stay device specific
FDA document K241284, dated 3 July 2024, names the da Vinci Surgical System IS5000. Its summary concerns increased uses and reprocessing cycles for two Force Feedback instruments: Mega SutureCut Needle Driver and ProGrasp Forceps. That document includes a needle-driver contraindication for hysterectomy and myomectomy. It is a historical, specific instrument record; it does not establish Ion clearance, approval of the whole portfolio, or today's complete indications. Procurement teams should obtain current local labeling for each quoted model and accessory. FDA K241284 letter and summary.
7. International procurement and official contact
On 2 March 2026, Intuitive reported completing acquisitions of distribution businesses and establishing direct operations in Italy, Spain, Portugal, Malta and San Marino, including associated territories. This documents a change in commercial organization, not universal product availability. European operations announcement.
Use Intuitive's official contact directory to reach the relevant regional product team. Request local availability, service coverage, installation requirements, instrument compatibility, recurring consumables, software access and a written commercial proposal. Published regional contacts do not determine a hospital's final price, delivery date or reimbursement position. Intuitive contact directory.
8. Evidence limits and related resources
This profile was reviewed on 10 September 2026 using manufacturer information and a device-specific FDA record. Company announcements establish what the supplier reports; they are not independent medical evidence or guarantees of outcomes. Product suitability requires the institution's clinical and technical review and current local instructions. Intuitive itself notes regional availability limits. Regional product and source disclosures.
Explore medical robotics, Write a Robotics Buyer Brief and Robotics RFQ.